Pancreatic Cancer Research

ResearcherShenzhen UniversityActive in the last 2 years

Wei Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6968-6974; OpenAlex author ID A5100441688. Sources: OpenAlex.

Their work

Papers
2 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. A novel BCAT1 inhibitor bufalin sensitizes pancreatic cancer cells to chemotherapy. Co-author DOI 10.1016/j.gendis.2024.101503↗
  2. CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancreatic cancer. First author DOI 10.1007/s00262-020-02500-3↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Milad Ashrafizadeh · 1 shared paper, 2025 · strength 0.25
  2. Xianbin Zhang · 1 shared paper, 2025 · strength 0.25
  3. Peng Gong · 1 shared paper, 2025 · strength 0.25
  4. Yingchao Wang · 1 shared paper, 2020 · strength 0.16
  5. Kai Liu · 1 shared paper, 2020 · strength 0.16
  6. Songyang Liu · 1 shared paper, 2020 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.